[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yi Zhang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100531339","moxibustion-for-the-prevention-of-hemorrhagic-cystitis-after-allo-hsct-100531339",false,"NCT06198517","Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT","Clinical Study of Moxibustion for the Prevention of Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF);\n2. Age: 14-60 years;\n3. Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT;\n\nExclusion Criteria:\n\n1. refuse to participate in this clinical study;\n2. The corresponding skin at the moxibustion site is broken or sensitive;\n3. allo-HSCT pretreated with the RIC program;","ALL","14 Years","60 Years",{"count":20,"type":21},266,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.",[27,28,29,30],"Moxibustion","Hematopoietic Stem Cell Transplantation","Hemorrhagic Cystitis","Prevention","RECRUITING","2026-03-09",{"date":34,"type":35},"2026-03-12","ACTUAL",{"date":37,"type":35},"2024-03-21",{"date":39,"type":21},"2026-09-30",{"name":41,"class":42},"Yi Zhang","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100555710","early-phase-1-genetically-modified-t-cells-treating-malignant-tumors-100555710","NCT06515626","Genetically Modified T Cells Treating Malignant Tumors","Clinical Study to Evaluate the Safety and Efficacy of Genetically Modified T Cells in the Treatment of Malignant Tumors","Inclusion Criteria:\n\n1. Subjects with malignant tumors confirmed by histopathology or cytology, including: non-small cell lung cancer, esophageal squamous cell carcinoma, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, kidney cancer, cervical squamous cell carcinoma, ovarian cancer, breast cancer, melanoma, and brain glia tumor, lymphoma, etc.;\n2. Age: 18 \\~ 75 years old; Gender: no limitation;\n3. Have sufficient hematopoietic capacity: ANC \\>1500 cells \u002Fmm3, Blood plate count \\>50,000 cells \u002Fmm3, HGB \\>9.0g\u002FdL, ALC \\>9 cells \u002Fmm3;\n4. Adequate liver and kidney function: AST and ALT ≤2.5 ULN in patients without liver metastasis and ≤5 times in patients with liver metastasis. ULN; Bilirubin ≤1.5 ULN (excluding hyperbilirubinemia or hyperbilirubin of non-hepatic origin); Creatinine ≤2.0 ULN. Creatinine clearance and creatinine clearance hormone ≥40 mL\u002Fmin;\n5. PT\u002FINR \\\u003C1.5 ULN, and PTT\u002FαPTT \\\u003C1.5 ULN;\n6. For desirable tumor tissues or tissue white tablets, positive expression of at least one of Mesothelin, NKG2D, HER2, CD276, CD19, BCMA and other antigens can be selected for clinical trials;\n7. ECOG physical status score 0 \\~ 2 points;\n8. Expected survival \\>6 months;\n9. Subject accepts voluntarily\n\nExclusion Criteria:\n\n1. Received anti-PD1, anti-PD-L1 or anti-PD-L2 antibody therapy or other immunotherapy methods one month before treatment with immune cells in this study;\n2. History of organ transplantation;\n3. Pregnancy or lactation;\n4. Positive for high baseline HBV DNA levels (≥2000 IU\u002Fml), HIV antibodies (anti-HIV), hepatitis C virus antibodies (anti-HCV), or treponema pallidum antibodies;\n5. There is active infection;\n6. There are active brain metastases (except asymptomatic or stable brain metastases after treatment);\n7. Combined with a second tumor; With the exception of patients with basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid cancer who achieved complete response to the second tumor for more than 5 years and did not require treatment during the study period;\n8. Severe autoimmune diseases such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, autoimmune vasculitis, or Wegener's granulomatosis require long-term (more than 2 months) systemic immunosuppressive therapy;\n9. People with allergies;\n10. NYHA heart failure grade ≥2 or hypertension can not be controlled after standard treatment, have a history of myocarditis or have a heart attack within one year;\n11. Thrombotic diseases with active bleeding that require treatment;\n12. Patients who are determined by the researcher to have a serious uncontrollable disease or other conditions that may affect the treatment in this study and are considered unsuitable.","18 Years","75 Years",{"count":54,"type":21},100,[56],"EARLY_PHASE1","To observe the safety, tolerability and initial effectiveness of gene modified T cell therapy in patients with malignant tumors in First Affiliated Hospital of Zhengzhou University, China.",[59],"Solid Tumor",[61],"CAR","2024-09-23",{"date":64,"type":35},"2024-09-25",{"date":66,"type":35},"2024-08-18",{"date":68,"type":21},"2027-12",{"name":41,"class":42},1,""]